News

Natural History Study of Huntington’s Fully Enrolled, Triplet Says

Triplet Therapeutics announced it has completed patient enrollment in SHIELD HD, a natural history study documenting the course of Huntington’s in the absence of treatment and associated disease biomarkers. With more than 60 people taking part, SHIELD HD (NCT04406636) has attained and exceeded its target enrollment goal ahead…

PDYN-derived Peptides Identified as Possible, Much-needed HD Biomarkers

Levels of proteins derived from prodynorphin (PDYN) — ultimately used during cell-to-cell signaling in the brain — are decreased in the fluid surrounding the brains of people with Huntington’s disease (HD), a new small study suggests. These findings indicate that PDYN-derived proteins could be used as specific biological…